KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Short-term Investments for 18 consecutive years, with $1.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Short-term Investments fell 7.19% year-over-year to $1.7 billion; the TTM value through Mar 2026 reached $1.7 billion, down 7.19%, while the annual FY2025 figure was $2.3 billion, 12.14% up from the prior year.
  • Short-term Investments hit $1.7 billion in Q1 2026 for Ionis Pharmaceuticals, down from $2.3 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.3 billion in Q4 2025 and bottomed at $1.5 billion in Q2 2022.
  • Average Short-term Investments over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • Year-over-year, Short-term Investments skyrocketed 37.3% in 2022 and then dropped 11.49% in 2025.
  • Ionis Pharmaceuticals' Short-term Investments stood at $1.7 billion in 2022, then grew by 12.95% to $1.9 billion in 2023, then increased by 6.4% to $2.1 billion in 2024, then increased by 12.14% to $2.3 billion in 2025, then decreased by 24.27% to $1.7 billion in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $1.7 billion, $2.3 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.